pubmed-article:20633036 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0019564 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0014556 | lld:lifeskim |
pubmed-article:20633036 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
pubmed-article:20633036 | pubmed:issue | 9 | lld:pubmed |
pubmed-article:20633036 | pubmed:dateCreated | 2010-9-13 | lld:pubmed |
pubmed-article:20633036 | pubmed:abstractText | Based on experimental findings, overexpression of P-glycoprotein at the blood-brain barrier has been suggested to be a contributor to pharmacoresistance of the epileptic brain. We test a technique for evaluation of interindividual differences of elevated transporter function, through microPET analysis of the impact of the P-glycoprotein modulator tariquidar. The preclinical study is intended for eventual translation to clinical research of patients with pharmacoresistant seizure disorders. | lld:pubmed |
pubmed-article:20633036 | pubmed:language | eng | lld:pubmed |
pubmed-article:20633036 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20633036 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20633036 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20633036 | pubmed:month | Sep | lld:pubmed |
pubmed-article:20633036 | pubmed:issn | 1528-1167 | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:PotschkaHeidr... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:BartensteinPe... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:CummingPaulP | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:WinterPetraP | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:XiongGuomingG | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:la... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:WänglerBjörnB | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:BöningGuidoG | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:PekcecAntonA | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:FuestChristin... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:SoerensenJonn... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:SchlichtigerJ... | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:BartmannHeroH | lld:pubmed |
pubmed-article:20633036 | pubmed:author | pubmed-author:JustTheresaT | lld:pubmed |
pubmed-article:20633036 | pubmed:copyrightInfo | Wiley Periodicals, Inc. © 2010 International League Against Epilepsy. | lld:pubmed |
pubmed-article:20633036 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20633036 | pubmed:volume | 51 | lld:pubmed |
pubmed-article:20633036 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20633036 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20633036 | pubmed:pagination | 1780-90 | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:meshHeading | pubmed-meshheading:20633036... | lld:pubmed |
pubmed-article:20633036 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20633036 | pubmed:articleTitle | Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. | lld:pubmed |
pubmed-article:20633036 | pubmed:affiliation | Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Munich, Germany. | lld:pubmed |
pubmed-article:20633036 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20633036 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20633036 | lld:pubmed |